Figure 5

LV transduction does not alter phenotypic and functional properties of DC2.4s and BMDCs. A) DC2.4/rHER-2 cells were treated with recombinant mIFN-γ to induce maturation. Light and dark grey dotted lines represent isotype antibody controls in samples without and with IFN-γ treatment, respectively. Orange and red solid lines represent CD80, CD86, and MHC II-A^b stained samples without and with mIFN-γ treatment, respectively. B, C) Culture supernatant was collected 24 hours after maturation with mIFN-γ and analyzed for mIL-6 and mTNF-α secretion by ELISA. White bars represent immature DC2.4s (no mIFN-γ treatment) and black bars represent mature DC2.4s (mIFN-γ treatment). Cytokine levels were reported in pg/mL of supernatant. Each treatment group was performed in triplicate. Each experiment was performed twice independently and representative data are shown with error bars representing standard deviations. *p values <0.05 were designated as significant (*). D) BMDCs were transduced with LV/rHER-2.c-FLIP_S at MOI of 20 and analyzed for rHER-2, CD11c, CD80, CD86, and MHC II-A^b expression with and without recombinant mTNF-α-induced maturation. Solid red line represents NT cells and light and dark blue shaded histograms represent immature and mature transduced BMDCs, respectively. Light and dark grey lines represent isotype antibody control stainings of transduced immature and mature BMDCs, respectively. This experiment was representative of three independent experiments.